Antimitochondrial antibodies and their significance in diffuse and limited scleroderma

Journal of Clinical Rheumatology

Volumn 5, Issue 4, 1999, Pages 206-209

  Pope, Janet E ^a,b   Thompson, Andrew ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Antimitochondrial antibodies; CREST; Primary biliary cirrhosis; Scleroderma

Indexed keywords

MITOCHONDRION ANTIBODY; URSODEOXYCHOLIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTPATIENT; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SCLERODERMA; SJOEGREN SYNDROME; SYMPTOMATOLOGY;

EID: 0032816718     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-199908000-00005     Document Type: Article

References (25)

1. Medsger TA Jr. Systemic sclerosis (scleroderma), eosinophilic fasciitis, and calcinosis. In: McCarty DJ, editor. Arthritis and allied conditions. 10th ed. Philadelphia: Lea and Febiger; 1985. p. 994-1036.
2. Le Roy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-4.
3. LaMont JT, Koff RS, Isselbacher KJ. Cirrhosis. In: Petersdorf RG, Adams RD, Braumvald E, Isselbacher KJ, Martin JB, Wilson JD, editors. Harrison's Principles of Internal Medicine. 10th ed. New York McGraw-Hffl; 1983. p. 1804-10.
4. Mehal WZ, Gregory WL, Lo Y-M D, Cross SJ, Fleming KA, Bassendine MF, et al. Defining the immunogenetic susceptibility to primary biliary cirrhosis. Hepatology 1994;20:1213-9.
5. Makinen, D, Fritzler M, Davis P, Sherlock S. Anticentromere antibodies in primary biliary cirrhosis. Arthritis Rheum 1983;26:914-7.
6. Reynolds TF, Denison EK, Frankl H, Lieberman FL, Petgers RL. Primary biliary cirrhosis with scleroderma, Raynaud's phenomenon and telangiectasia. Am J Med 1971;50:302-12.
7. Powell FC, Schroeter AL, Dickson ER. Primary biliary cirrhosis and the CREST syndrome: A report of 22 cases. Q J Med 1987;62:75-81.
8. Murray-Lyon IM, Thompson RPH, Ansell ID, Williams R. Scleroderma and primary biliary cirrhosis. Br Med J 1970;3:258-9.
9. Clarke AK, Galbraith RM, Hamilton EBD, Williams R. Rheumatic disorders in primary biliary cirrhosis. Rheumatic disorders in primary biliary cirrhosis. Ann Rheum Dis 1978; 37:42-7.
10. Zurgil N, Bakimer R, Moutsopoulos HM, Tzioufas AG, et al. Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. J Clin Immunol 1992;12:201-9.
11. Whyte J, Hough D, Maddison PJ, McHugh NJ. The association of primary biliary cirrhosis and systemic sclerosis is not accounted for by cross reactivity between mitochondrial and centromere antigens. J Autoimmunity 1994;7: 413-24.
12. Fregeau DR, Leung PSC, Coppel RL, McNeilage LJ, Medsger TA, Gershwin ME. Autoantibodies to mitochondria in systemic sclerosis. Arthritis Rheum 1988;31:386-92.
13. Munoz LE, Thomas HC, Scheuer PJ, Doniach D, Sherlock S. Is mitochondrial antibody diagnostic of primary biliary cirrhosis? Gut 1981;22:136-40.
14. Mouritsen S, Demant E, Permin A, Wiik A. High prevalence of anti-mitochondrial antibodies among patients with some well-defined connective tissue diseases. Clin Exp Immunol 1986;66:68-76.
15. Preliminary criteria for the classification of systemic sclerosis (scleroderma): Special article. Arthritis Rheum 1980;23:581-90.
16. Storch VV. Standardized indirect immunofluorescence. Differentiation of mitochondrial, microsomal and ribosomal antibodies. Z Gesamte Inn Med 1977;32:60-3.
17. Bernstein RM, Callender ME, Neuberger JM, Hughes GRV, Williams R. Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis 1982;41:612-4.
18. Meek F, Khoury EL, Doniach D, Baum H. Mitochondrial antibodies in chronic liver diseases and connective tissue disorders: further characterization of autoantigens. Clin Exp Immunol 1980;41:43-54.
19. Alderuccio F, Toh B-H, Barnett AJ, Pedersen JS. Identification and characterization of mitochondria autoantigens in progressive systemic sclerosis: identity with the 72,000 dalton autoantigen in primary biliary cirrhosis. J Immunol 1986;137:1855-9.
20. McHugh NJ, James IE, Fairburn K, Maddison PJ. Autoantibodies to mitochondrial and centromere antigens in primary biliary cirrhosis and systemic sclerosis. Clin Exp Immunol 1990;81:244-9.
21. Hirakata M, Akizuki M, Miyachi K, Matsushima H, Okano T, Homma M. Coexistence of CREST syndrome and primary biliary cirrhosis. Serological studies of two cases. J Rheumatol 1988;15:1166-70.
22. Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OFW. Natural history of early primary biliary cirrhosis. Lancet 1996;348:1399-402.
23. Fujimoto M, Sato S, Ihn H, Kiruchi K, Tamaki K, Takehara K. Autoantibodies to pyruvate dehydrogenase complex in patients with systemic sclerosis. Possible role of anti-El alpha antibody as a serologic indicator for development of primary biliary cirrhosis. Arthritis Rheum 1995;38:985-9.
24. Poupon RE, Balkan B, Eschwage E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. New Engl J Med 1991;30:1548-54.
25. Heathcote EJ, Caech-Dudek K, Walker V, Barley RJ, Bleachs LM, Ghent CN, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-56.